Loading...
Trabectedin for advanced soft tissue sarcomas: optimizing use
Patients with locally advanced or metastatic soft tissue sarcoma have a poor outlook with median survival in the order of 1 year. There is therefore an urgent need for novel agents to impact this disease. Trabectedin is one such novel agent that has demonstrated activity for patients with advanced s...
Saved in:
| Published in: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4270297/ https://ncbi.nlm.nih.gov/pubmed/25540587 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S49330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|